Morgan Stanley Maintains Overweight on Corteva, Raises Price Target to $95

Benzinga Newsdesk www.benzinga.com Positive 77.3%

Neg 0% Neu 0% Pos 77.3%

Morgan Stanley analyst Vincent Andrews maintains Corteva (NYSE:CTVA) with a Overweight and raises the price target from $84 to $95.